[go: up one dir, main page]

PL2532743T3 - Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka - Google Patents

Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka

Info

Publication number
PL2532743T3
PL2532743T3 PL11739882T PL11739882T PL2532743T3 PL 2532743 T3 PL2532743 T3 PL 2532743T3 PL 11739882 T PL11739882 T PL 11739882T PL 11739882 T PL11739882 T PL 11739882T PL 2532743 T3 PL2532743 T3 PL 2532743T3
Authority
PL
Poland
Prior art keywords
cancer
prevention
treatment
pharmaceutical composition
pharmaceutical
Prior art date
Application number
PL11739882T
Other languages
English (en)
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2532743T3 publication Critical patent/PL2532743T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11739882T 2010-02-04 2011-02-04 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka PL2532743T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010023454 2010-02-04
JP2010183162 2010-08-18
EP11739882.6A EP2532743B1 (en) 2010-02-04 2011-02-04 Pharmaceutical composition for treatment and/or prevention of cancer
PCT/JP2011/052413 WO2011096534A1 (ja) 2010-02-04 2011-02-04 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
PL2532743T3 true PL2532743T3 (pl) 2015-09-30

Family

ID=44355528

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11739882T PL2532743T3 (pl) 2010-02-04 2011-02-04 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka

Country Status (14)

Country Link
US (2) US8828398B2 (pl)
EP (1) EP2532743B1 (pl)
JP (1) JP5906739B2 (pl)
KR (1) KR101805520B1 (pl)
CN (1) CN102822335B (pl)
AU (1) AU2011211699B2 (pl)
BR (1) BR112012018949A2 (pl)
CA (1) CA2788718C (pl)
ES (1) ES2540858T3 (pl)
MX (1) MX340015B (pl)
PL (1) PL2532743T3 (pl)
PT (1) PT2532743E (pl)
RU (1) RU2603742C2 (pl)
WO (1) WO2011096534A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911925B8 (pt) * 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
CN102170907A (zh) 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
MX2012008991A (es) 2010-02-04 2012-09-07 Toray Industries Medicamento para tratar y/o prevenir el cancer.
JP5742714B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び/又は予防用医薬組成物
PL2532743T3 (pl) 2010-02-04 2015-09-30 Toray Industries Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
EP2532366B1 (en) 2010-02-04 2016-09-07 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
ES2583777T3 (es) 2010-02-04 2016-09-22 Toray Industries, Inc. Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer
DK3604339T3 (da) 2011-01-14 2021-04-12 Univ California Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse af samme
RU2610428C2 (ru) 2011-08-04 2017-02-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
ES2634249T3 (es) 2011-08-04 2017-09-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
WO2013018883A1 (ja) * 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び/又は予防用医薬組成物
DK2740489T3 (en) 2011-08-04 2017-01-16 Toray Industries Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
TR201802089T4 (tr) 2011-08-04 2018-03-21 Toray Industries Kanserin tedavisi ve/veya önlenmesi amacına yönelik ilaç bileşimi.
EP2741085B1 (en) 2011-08-04 2017-04-05 Toray Industries, Inc. Method for detecting pancreatic cancer
BR112014002618B1 (pt) 2011-08-04 2022-09-20 Toray Industries, Inc Anticorpo, composição farmacêutica, dna, uso de um anticorpo e uso de uma composição farmacêutica
IN2014KN01715A (pl) 2012-02-21 2015-10-23 Toray Industries
CN104114581B (zh) * 2012-02-21 2018-11-30 东丽株式会社 癌的治疗和/或预防用药物组合物
WO2013125636A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
HUE045461T2 (hu) * 2012-02-21 2019-12-30 Toray Industries Gyógyászati készítmény rák kezelésére
ES2656620T3 (es) 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
JP6244912B2 (ja) 2012-07-19 2017-12-13 東レ株式会社 癌の検出方法
HUE043162T2 (hu) * 2012-07-19 2019-08-28 Toray Industries Eljárás rák detektálására
TR201819812T4 (tr) 2013-08-09 2019-01-21 Toray Industries Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim
KR102590454B1 (ko) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
KR20190075921A (ko) 2016-10-28 2019-07-01 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
KR101872193B1 (ko) 2017-02-06 2018-08-03 (주)엘에프라이팅 안정기함
US20210121562A1 (en) 2018-03-30 2021-04-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Her2を標的とする免疫結合体
CA3175137A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
BR112022018161A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
WO2021182570A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
WO2021182571A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
BR112022018171A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
KR20240024074A (ko) 2021-06-23 2024-02-23 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
MX2023014500A (es) 2021-06-23 2024-01-25 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
WO2023278631A1 (en) * 2021-06-29 2023-01-05 Tega Therapeutics, Inc. Heparin from modified mst cells and methods of making and using
EP4378476A4 (en) 2021-07-27 2025-07-23 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20250281607A1 (en) 2021-07-27 2025-09-11 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN117651566A (zh) 2021-07-27 2024-03-05 东丽株式会社 用于癌的治疗和/或预防的药品
KR20240051956A (ko) 2021-09-03 2024-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
AU2023329564A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4578457A1 (en) 2022-08-24 2025-07-02 Toray Industries, Inc. Pharmaceutical for treating and/or preventing cancer
JPWO2024043257A1 (pl) 2022-08-24 2024-02-29
AU2023334695A1 (en) 2022-08-30 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN119768184A (zh) 2022-08-30 2025-04-04 东丽株式会社 用于癌的治疗和/或预防的药品
WO2024135809A1 (ja) 2022-12-23 2024-06-27 東レ株式会社 癌の治療及び/又は予防のための医薬品
KR20250166224A (ko) 2023-03-28 2025-11-27 도레이 카부시키가이샤 세포막 단백질을 검출하는 방법
JPWO2024204685A1 (pl) 2023-03-31 2024-10-03
WO2025058000A1 (ja) * 2023-09-13 2025-03-20 東レ株式会社 癌の治療、予防及び/又は診断用医薬組成物

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU693459B2 (en) * 1993-08-09 1998-07-02 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
HU221385B1 (en) 1994-07-13 2002-09-28 Chugai Pharmaceutical Co Ltd Reconstituted human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
CA2325346A1 (en) 1998-04-03 1999-10-14 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
WO2000060077A2 (en) 1999-04-02 2000-10-12 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2388822A1 (en) 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
DE60227067D1 (de) 2001-05-11 2008-07-24 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
RU2203620C1 (ru) * 2001-09-21 2003-05-10 Московский областной научно-исследовательский клинический институт Способ определения ангиогенеза глиомы
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS OF TREATING IMMUNE-INFLAMMATORY DISEASES
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
WO2005116076A2 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
EP2332990A1 (en) 2004-03-19 2011-06-15 Imclone LLC Human anti-epidermal growth factor receptor antibody
ATE515515T1 (de) 2004-03-30 2011-07-15 Glaxo Group Ltd Immunglobuline gegen menschlisches osm
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
CN101189516A (zh) 2005-03-11 2008-05-28 赛弗吉生物系统公司 卵巢癌及子宫内膜癌的生物标记:抗菌蛋白(hepcidin)
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
JP5490413B2 (ja) 2006-01-05 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロrna発現異常
CA2642342A1 (en) * 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
PT2207037T (pt) 2007-10-25 2016-12-09 Toray Industries Método para a deteção de cancro
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
NZ621433A (en) 2008-03-18 2015-10-30 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
JP4916030B2 (ja) 2008-07-24 2012-04-11 パナソニック株式会社 面材と桟材との接着方法及びその接着装置
CN102170907A (zh) * 2008-08-05 2011-08-31 东丽株式会社 用于治疗和预防癌症的药物组合物
ES2619322T3 (es) 2008-08-05 2017-06-26 Toray Industries, Inc. Agente inductor de inmunidad
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
JP2010183162A (ja) 2009-02-03 2010-08-19 Mitsubishi Electric Corp 動画像符号化装置
EP2467401B1 (en) 2009-08-19 2017-01-18 Merck Patent GmbH Antibodies for the detection of integrin complexes in ffpe material
MX2012003404A (es) 2009-09-22 2012-09-12 Volker Sandig Procedimiento para producir moleculas que contienen estructuras de glicano especializadas.
JP5742714B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び/又は予防用医薬組成物
ES2583777T3 (es) 2010-02-04 2016-09-22 Toray Industries, Inc. Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer
PL2532743T3 (pl) 2010-02-04 2015-09-30 Toray Industries Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
JP5845899B2 (ja) * 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
MX2012008991A (es) 2010-02-04 2012-09-07 Toray Industries Medicamento para tratar y/o prevenir el cancer.
EP2532366B1 (en) 2010-02-04 2016-09-07 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
WO2012005550A2 (ko) 2010-07-08 2012-01-12 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
CN103261224B (zh) 2010-07-26 2015-10-07 瑟维尔实验室 用于肝癌治疗的方法和组合物
EP2741085B1 (en) 2011-08-04 2017-04-05 Toray Industries, Inc. Method for detecting pancreatic cancer
RU2610428C2 (ru) * 2011-08-04 2017-02-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
ES2634249T3 (es) 2011-08-04 2017-09-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
TR201802089T4 (tr) * 2011-08-04 2018-03-21 Toray Industries Kanserin tedavisi ve/veya önlenmesi amacına yönelik ilaç bileşimi.
BR112014002618B1 (pt) * 2011-08-04 2022-09-20 Toray Industries, Inc Anticorpo, composição farmacêutica, dna, uso de um anticorpo e uso de uma composição farmacêutica
DK2740489T3 (en) * 2011-08-04 2017-01-16 Toray Industries Pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
WO2013018883A1 (ja) * 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び/又は予防用医薬組成物
JP5455993B2 (ja) 2011-08-30 2014-03-26 キヤノン株式会社 クリーニング装置、プロセスカートリッジ、及び画像形成装置
HUE045461T2 (hu) * 2012-02-21 2019-12-30 Toray Industries Gyógyászati készítmény rák kezelésére
IN2014KN01715A (pl) * 2012-02-21 2015-10-23 Toray Industries
WO2013125636A1 (ja) * 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
CN104114581B (zh) * 2012-02-21 2018-11-30 东丽株式会社 癌的治疗和/或预防用药物组合物
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
ES2656620T3 (es) 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado

Also Published As

Publication number Publication date
MX2012008998A (es) 2012-08-31
EP2532743B1 (en) 2015-04-15
MX340015B (es) 2016-06-22
KR101805520B1 (ko) 2017-12-07
ES2540858T3 (es) 2015-07-14
KR20130004277A (ko) 2013-01-09
US20140341919A1 (en) 2014-11-20
WO2011096534A1 (ja) 2011-08-11
EP2532743A1 (en) 2012-12-12
CN102822335A (zh) 2012-12-12
US9416191B2 (en) 2016-08-16
JP5906739B2 (ja) 2016-04-20
CN102822335B (zh) 2015-09-30
US8828398B2 (en) 2014-09-09
US20120301471A1 (en) 2012-11-29
AU2011211699A1 (en) 2012-08-23
CA2788718A1 (en) 2011-08-11
RU2012137502A (ru) 2014-03-10
BR112012018949A2 (pt) 2020-09-01
CA2788718C (en) 2019-05-21
RU2603742C2 (ru) 2016-11-27
AU2011211699B2 (en) 2015-01-22
PT2532743E (pt) 2015-08-04
EP2532743A4 (en) 2013-09-11
JPWO2011096534A1 (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
PL2532365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
PL2532743T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
HUE040012T2 (hu) Gyógyászati ágens rák kezelésére és/vagy megelõzésére
HUE046788T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
PT2740489T (pt) Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
PL2832365T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
PT2740793T (pt) Composição de fármacos para o tratamento e/ou a prevenção de cancro
IL225471B (en) Preparations for the prevention and treatment of cancer
PL2532366T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
PL2322221T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania raka
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
PL2532680T3 (pl) Kompozycja medyczna do leczenia raka i/lub zapobiegania
HUE036425T2 (hu) Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére
PL2740796T3 (pl) Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi
PT2740794T (pt) Composição farmacêutica para o tratamento e/ou profilaxia de cancro
EP3031826A4 (en) Pharmaceutical composition for treatment and/or prevention of cancer
IL219073A (en) A drug combination for cancer treatment
IL251083A0 (en) Compounds and preparations for the treatment of cancer
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
PL2305300T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
AU2011211693B2 (en) Pharmaceutical composition for treating and/or preventing cancer
HU1000559D0 (en) Pharmaceutical compositions for the treatment of osteoporosis and cancer
HK1189502A (en) Compositions and methods for the prevention and treatment of cancer